Medicine and Dentistry
COVID-19
100%
Arm
100%
Baricitinib
100%
Ravulizumab
100%
Interim Analysis
22%
Complement Component C5
22%
Public Health
11%
Hazard Ratio
11%
Biomedical Research
11%
Intensive Care Unit
11%
Complement Activation
11%
Renal Failure
11%
Care Group
11%
Immunosuppressant
11%
Cardiovascular System
11%
Medical Research
11%
Extracorporeal Membrane Oxygenation
11%
Artificial Respiration
11%
Diseases
11%
Janus Kinase
11%
Janus Kinase 1
11%
Complement Component C5a
11%
Cytokine
11%
Disease Severity
11%
Adverse Event
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ravulizumab
100%
Baricitinib
100%
Complement Component C5
22%
Cytokine
11%
Disease Severity
11%
Janus Kinase 1
11%
Kidney Failure
11%
Janus Kinase
11%
Immunosuppressive Agent
11%
Pandemic
11%
Adverse Event
11%
Repurposing
11%
Complement Component C5a
11%
Diseases
11%